Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS
Corvus Pharma: Soquelitinib Advancing Towards Initial Enrollment for Registrational Phase 3 Clinical Trial for PTCL and Randomized Phase 1 Clinical Trial for Atopic Dermatitis >CRVS
Corvus Pharma：索克利替尼即將進行PTCL的註冊性3期臨床試驗和特應性皮炎的隨機1期臨床試驗 >CRVS 的初始入組
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊